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Background: Signal transducer and activator of transcription 3 (STAT3) plays a critical role in tumor development
by regulating signaling pathways involved in cell proliferation, survival, metastasis and angiogenesis. STAT3 is
activated in many cancers, including head and neck squamous cell carcinoma (HNSCC) in people. Feline oral
squamous cell carcinoma (OSCC) is similar to advanced or recurrent HNSCC as it is poorly responsive to traditional
therapies and carries a poor long-term prognosis. The purpose of this study was to characterize expression and
activation of STAT3 in feline OSCC cell lines and tumor samples and to investigate the biologic activity of a novel,
allosteric STAT3 inhibitor, LLL12, in feline OSCC cell lines.
Results: We evaluated 3 feline OSCC cell lines and one of these (SCCF2) exhibited high levels of constitutive STAT3
phosphorylation and high sensitivity to LLL12 treatment. Exposure of SCCF2 cells to LLL12 resulted in decreased
expression of pSTAT3 and total STAT3, apoptosis as assessed by caspase 3/7 activation, inhibition of colony
formation and reduced expression of the STAT3 transcriptional target survivin. In contrast, the STAT3 transcriptional
targets VEGF and MCL-1 increased after LLL12 treatment. This was, in part, likely due to LLL12 mediated
upregulation of HIF-1α, which is known to drive VEGF and MCL-1 expression. The OSCC cell lines with low basal
STAT3 phosphorylation did not exhibit these effects, suggesting that STAT3 inhibition was responsible for the
observed results. Lastly, immunohistochemistry for pSTAT3 was performed using a feline OSCC tissue microarray,
demonstrating expression in 48 % of samples tested.
Conclusions: These data demonstrate that LLL12 has biologic activity against a feline OSCC cell line expressing pSTAT3
and that STAT3 represents a target for therapeutic intervention in this disease. However, given the up-regulation of
several STAT3 transcriptional targets following treatment, further investigation of STAT3 and its related signaling pathways
in OSCC is warranted.
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The signal transducer and activator of transcription (STAT)
family of proteins consists of seven isoforms that are tran-
scription factors responsible for relaying signals from extra-
cellular growth factors and cytokines, thereby influencing
normal cellular physiology and development. Due to their* Correspondence: london.20@osu.edu
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proteins, in particular STAT3 and STAT5, also have been
implicated in cancer initiation and progression [1]. Initial
evidence of the role of STAT proteins in tumor biology
came from the discovery that activated STAT3 was required
for cellular transformation by the viral oncogene, v-src
[1, 2]. There is now substantial data supporting the role of
STAT proteins in cancer biology, including the observation
that constitutive activation of STAT3 is present in a variety
of human malignancies [1, 3].is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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to be primarily driven by the Janus kinase (JAK) family
members following cytokine receptor signaling, it is now
evident that substantial cross-talk exists between receptor
and non-receptor kinases (e.g. EGFR, Src), and this also
contributes to the activation of STAT3 [4, 5]. After phos-
phorylation of the critical tyrosine residue (Tyr705),
STAT3 homodimerization occurs followed by nuclear
translocation and alteration of gene transcription. In nor-
mal cells, STAT3 activation is transient due to endogenous
regulating proteins including SH2-containing phosphatases
(SHPs), protein inhibitors of activated STAT3 (PIAS3) and
suppressors of cytokine signaling (SOCS) [6]. Since activat-
ing mutations of STAT3 are rare [7], constitutive phosphor-
ylation of STAT3 is generally the result of aberrations in
upstream signaling proteins or physiologic regulators [5, 8].
Importantly, constitutive STAT3 activation contributes to
metastasis and chemotherapy resistance through its effects
on several transcriptional targets, including VEGF, survivin
and Bcl2 family members. As such, it represents a poten-
tially relevant target for therapeutic intervention in many
cancers and several inhibitors of STAT3 are currently under
investigation [9, 10]. Recently, the role of STAT3 in human
head and neck squamous cell carcinoma (HNSCC) has re-
ceived significant attention as constitutive activation has
been demonstrated in several HNSCC cell lines [11, 12]. In-
hibition of STAT3 with dominant negative constructs or
antisense oligonucleotides promoted downregulation of
expression of STAT3 transcriptional targets, growth in-
hibition and induction of apoptosis in HNSCC cell
lines, suggesting that STAT3 is necessary for growth
and survival of HNSCC cells [11]. Similar results were
generated in HNSCC murine xenograft models treated
with STAT3 decoys or siRNA [13]. Lastly, STAT3 phos-
phorylation was found in HNSCC tumor samples and
has been associated with a poor prognosis [14].
Similar to people, squamous cell carcinoma (SCC) is the
most common oral malignancy in cats, representing 61 %
of oral tumors [15]. Feline oral SCC (OSCC) is locally inva-
sive, rapidly progressive and poorly responsive to traditional
therapies such as radiation therapy and chemotherapy. In
most cases, OSCC arising from the gingiva exhibits bone
invasive properties early in the course of disease, causing
substantial morbidity in the form of anorexia and pain. Fur-
thermore, as OSCC primarily occurs in older cats, it is
often mistaken for dental disease resulting in advanced
tumor stage at the time of diagnosis. The overall prognosis
for cats diagnosed with OSCC is poor, with a one year sur-
vival rate of less than 10 % [16]. In rare cases, surgery
followed by radiation therapy may provide adequate
tumor control in patients with small tumors or tumors
located in the rostral mandible [17]. However, recurrence
rates following surgery are generally considered unaccept-
ably high and acute and long-term post-surgical morbiditiesare common [17, 18]. Radiation therapy is also considered
ineffective in management of OSCC as both definitive and
hypofractionated protocols fail to extend survival beyond
2–3 months in most instances [19, 20]. Finally, chemother-
apy alone has minimal benefit in treatment of OSCC [21];
however, the combination of radiation therapy and chemo-
therapy or radiosensitizers results in modest improvements
in response rates and outcomes [22] but use is limited by
increased local and systemic toxicity [23].
Given the similarities between feline and human SCC
and the paucity of effective treatments in cats with this dis-
ease, we sought to determine whether STAT3 plays a role
in feline OSCC. In previous studies we have shown that the
allosteric, small molecule inhibitor, LLL12, is a potent and
selective inhibitor of STAT3 phosphorylation [24]. Specific-
ally, LLL12 reduces STAT3 phosphorylation, inhibits prolif-
eration, and induces apoptosis in a variety of canine and
human cell lines (breast, pancreatic, glioblastoma, osteosar-
coma) and inhibits tumor growth and angiogenesis in sev-
eral murine tumor xenograft models [24–26]. As such, the
purpose of this study was to characterize activation and
expression of phosphorylated STAT3 (pSTAT3) in feline
OSCC cell lines and tumor samples and to investigate the
biologic activity of LLL12 in feline OSCC cell lines.
Methods
Cell lines and reagents
Feline OSCC lines SCCF1, SCCF2 and SCCF3 were pre-
viously established and characterized by one of the investi-
gators (TJR) [27, 28]. The SCCF1, SCCF2 and SCCF3 cell
lines were derived from a laryngeal, bone-invasive gingival
and lingual SCC, respectively. Cell lines were maintained
in DMEM supplemented with 10 % FBS, non-essential
amino acids, sodium pyruvate, penicillin, streptomycin,
L-glutamine, and HEPES (4-(2-hydroxythyl)-1-piperazi-
neethanesolfonic acid) at 35 °C, supplemented with 5 %
CO2. LLL12 was synthesized and purified as previously
described and provided by Dr. Chenglong Li (College of
Pharmacy, The Ohio State University) [24]. Aliquots of
the stock solution were stored at -20 °C until use. The
proteasome inhibitor MG132 was purchased from Cal-
biochem (Billerica, MA). The following antibodies were
used for Western blotting and/or immunohistochemistry
experiments: pSTAT3 (Y705, Cell Signaling Technology,
Danvers, MA), STAT3 (Cell Signaling Technology), sur-
vivin (Novus Biologicals, Littleton, CO), pAKT (Ser473,
Cell Signaling Technology), AKT (BD Biosciences, San
Jose, CA) and β-actin (Santa Cruz Biotechnology, Santa
Cruz, CA).
Cell proliferation
Optimal 96-well plating densities were determined for each
cell line. This was defined as the concentration of cells at
which proliferation occurred but cell confluence and/or
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cells (SCCF1: 1 × 104; SCCF2: 1 × 104; SCCF3: 5 × 103)
were seeded in triplicate in 96-well plates overnight in
10 % FBS supplemented medium and incubated with
DMSO or increasing concentrations of LLL12. After 24 h,
the medium was removed and the plates were frozen
at -80 °C overnight before processing using the CyQUANT®
Cell Proliferation Assay Kit (Molecular Probes, Eugene, OR)
according to the manufacturer’s instructions. Cell prolifera-
tion was calculated as a percentage of the DMSO-treated
control wells and IC50 values were derived after plotting pro-
liferation values on a logarithmic curve.
Detection of apoptosis
Feline OSCC cells (SCCF2: 1 × 104; SCCF3: 5 × 103) were
seeded in triplicate in 96-well plates overnight in 10 %
FBS supplemented medium and incubated with DMSO or
increasing concentrations of LLL12 for 12 or 24 h. Cas-
pase 3/7 activity was determined using the SensoLyte
Homogenous AMC Caspase 3/7 Assay (Anaspec Inc, San
Jose, CA) according to the manufacturer’s instructions.
Clonogenic assay
SCCF2 and SCCF3 cells were grown in flasks until ap-
proximately 80 % confluent, then collected, washed and
plated at 1,000 cells per well in six-well plates in 10 %
FBS supplemented medium. After 24 h, the cells were
treated with DMSO, 0.02, 0.2 or 2 μM LLL12 and incu-
bated at 35 °C, supplemented with 5 % CO2 until colony
formation was observed in DMSO treated control wells.
Cells were then fixed with methanol/acetic acid (3:1),
washed with PBS, stained with crystal violet (0.2 g/L)
and colonies consisting of greater than 50 cells were
counted. After counting colonies, plating efficiency and
survival fraction were calculated. Plating efficiency was
defined as the number of colonies formed divided by the
number of cells seeded in DMSO treated groups. Sur-
vival fraction was defined as the number of colonies
formed divided by the number of cells seeded in LLL12
treated groups, normalized to the plating efficiency [29].
Western blotting
Cell lines were cultured in 10 % FBS supplemented medium
until 80 % confluent. Protein lysates were prepared and
quantified, 100 μg of protein was separated by SDS-PAGE
and Western blotting for pSTAT3 and STAT3 was per-
formed as previously described [30]. To evaluate effects of
LLL12 treatment, SCCF2 and SCCF3 cells (1 × 107) were
cultured in 1 % FBS supplemented medium and treated with
DMSO, 0.2 μM LLL12 alone, 10 μM MG132 alone or
MG132 in combination with LLL12 for 12 h. Protein lysate
preparation, quantification and Western blotting were re-
peated as described above. The membranes were incubated
overnight with anti-pSTAT3, anti-survivin or anti-pAKTantibodies incubated with the appropriate horseradish
peroxidase-linked secondary antibodies, washed, and ex-
posed to substrate (SuperSignal West Dura Extended Dur-
ation Substrate, Pierce, Rockford, IL). Blots were stripped,
washed, and re-probed for total STAT3, AKT or β-actin.
RT-PCR and qRT-PCR
Total RNA was extracted from SCCF2 and SCCF3 cells
cultured in 1 % FBS supplemented medium following 12 h
of treatment with DMSO or 0.2 μM LLL12, using TRIzol
reagent (Invitrogen, Carlsbad, CA). cDNA was made from
2 μg of total RNA using Superscript III (Invitrogen) accord-
ing to the manufacturer’s instructions. For each PCR reac-
tion, 1/20th of the resultant cDNA was used in a total
volume of 25 μL. Primers designed and utilized for feline
survivin, VEGF, STAT3, HIF-1α, cyclin D1, MCL-1 and
GAPDH are listed in Additional file 1: Table S1. An anneal-
ing temperature of 60 °C was used for all reactions. Stand-
ard PCR was performed with all primer sets and amplicon
length was verified through agarose gel electrophoresis and
visualization of PCR products using the Alpha Imager sys-
tem (Alpha Innotech Corp, San Leandro, CA).
To quantitatively measure the effect of LLL12 treatment
on STAT3 gene expression as well as downstream targets,
total RNA was collected using the methods described
above. Real-time quantitative PCR was performed using
Applied Biosystem’s StepOne Plus Real-Time PCR system
(Applied Biosystems, Foster City, CA). Feline survivin,
VEGF, STAT3, HIF-1α, cyclin D1, MCL-1 and GAPDH
were detected using Fast SYBR Green PCR Master Mix
(Applied Biosystems) according to the manufacturer’s in-
structions. All reactions were performed in triplicate and
included non-template controls for each gene. Relative ex-
pression was calculated using the comparative threshold
cycle method. With this method, the cycle threshold
(CT) values are compared between the sample of inter-
est and a non-treated sample. The CT values of both
samples are normalized to an endogenous housekeep-
ing gene, GAPDH [31].
Tissue microarray construction and immunohistochemistry
To assess the prevalence of STAT3 activation in primary
feline OSCC samples, a tissue microarray (TMA) was
made from archived feline OSCC surgical biopsies and
immunohistochemistry for pSTAT3 was performed. Sur-
gical biopsies were obtained and evaluated microscopic-
ally to confirm the presence of OSCC as previously
described [32]. Representative areas of tumor tissue were
identified on hematoxylin and eosin (HE) stained sec-
tions by a single pathologist (CP) for 1.5 mm core sam-
pling. Cores were extracted from the corresponding areas
on thirty-seven paraffin embedded tissue blocks and
inserted into predetermined sites on the TMA recipient
block. Immunohistochemical staining was performed for
Fig. 1 Activation of STAT3 in feline OSCC cell lines. Protein lysates
were generated from the three untreated cell lines, separated by
SDS-PAGE and Western blotting for pSTAT3 (Y705), STAT3 and β-actin
was performed
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taining tissue sections were deparaffinized in xylene and
rehydrated in distilled water. Slides were then placed in
plastic coplin jars containing Target Retrieval Solution
(Target Retrieval Solution, pH 6.0, Dako, Glostrup,
Denmark) and then enclosed in a decloaking chamber con-
taining distilled water. Antigen retrieval was performed by
heating the slides to 125 °C for 15 min; slides were allowed
to cool to 90 °C for 10 s followed by cooling at room
temperature for 10 min. Endogenous peroxidase activity
was quenched by immersion in 3 % hydrogen peroxide for
10 min. Non-specific binding was blocked by incubation
with serum-free protein block (Dako) for 10 min. Slides
were incubated for 30 min at room temperature with anti-
pSTAT3 antibody at a dilution of 1:100 in antibody diluent
(Dako). After rinsing in wash buffer, biotinylated goat-anti-
rabbit secondary antibody was applied at a dilution of
1:200 for 30 min. All slides were rinsed and then incubated
with Vector RTU ABC Elite complex (Vector Laboratories,
Burlingame, CA) for 30 min followed by incubation with
DAB chromagen for 5 min. Finally, slides were counter-
stained with hematoxylin, rinsed, dehydrated with ethanol
and fitted with coverslips. For negative controls, staining
procedures were carried out as above but without the
addition of a primary antibody. Mouse lymph node served
as a positive control. The construction of the tissue micro-
array and immunohistochemistry were performed by the
OSU-CVM Veterinary Biosciences Comparative Pathology
and Mouse Phenotyping Shared Resource Histology/IHC
Core Lab.
Slides were evaluated by light microscopy to assess pSTA3
immunoreactivity. Overall pSTAT3 signal intensity of OSCC
cells was subjectively scored from 0 to 3 (0 = none to weak,
1 =mild, 2 =moderate, 3 = strong), with strong reactivity
defined as staining intensity of the positive control. The per-
centage of positive cells was also estimated and scored as
follows: <5 % = 0, 5–20 %= 1, 20–50 %= 2, 50–100 %= 3. A
total score was obtained by adding the score of signal inten-
sity and percentage positivity. Total scores greater than or
equal to 2 were considered positive. The distribution of
pSTAT3 immunoreactivity was noted as nuclear in both
positive control and OSCC samples.
Statistical analysis
All experiments were performed in triplicate and/or re-
peated three times. All values reported are mean ±
standard deviation. A one-way ANOVA comparison
(parametric data) or Kruskal-Wallis test (non-paramet-
ric data) was performed to compare multiple treatment
groups in the cell proliferation, caspase and colony for-
mation assays. An independent samples t-test (paramet-
ric data) or Mann–Whitney U test (non-parametric
data) was performed to evaluate differences in gene ex-
pression between LLL12 treated groups and DMSOtreated controls for real-time quantitative PCR assays.
Values of p < 0.05 were considered statistically significant.Results
Constitutive phosphorylation of STAT3 is variable in
feline OSCC cell lines and correlates with response to
LLL12
To assess whether STAT3 is constitutively activated in fe-
line OSCC cell lines, Western blotting was performed to
evaluate for the presence of pSTAT3. As shown in Fig. 1,
only one of the three cell lines, SCCF2, demonstrated high
levels of pSTAT3 when compared to the others. All three
OSCC cell lines were then incubated with increasing con-
centrations of LLL12 (0.01 μM – 10 μM) for 24 h and cell
proliferation was assessed. While LLL12 significantly re-
duced cell proliferation in all cell lines (p < 0.005), SCCF2
was most sensitive to LLL12, with a calculated IC50 concen-
tration in the nanomolar range (180 nM), correlating with
the highest level of basal STAT3 phosphorylation (Fig. 2).Treatment with LLL12 inhibits pSTAT3 and STAT3
expression in feline OSCC cells that express elevated
levels of pSTAT3
To assess the direct effects of LLL12 on pSTAT3, two
OSCC cell lines with high (SCCF2) and low (SCCF3)
basal STAT3 activation were chosen for further analysis.
Cells were treated with DMSO or 0.2 μM LLL12 for
12 h and Western blotting for pSTAT3 and STAT3 was
performed. Western blot analyses revealed that pSTAT3
and, to a lesser degree, total STAT3, were both downreg-
ulated in SCCF2 following treatment with LLL12
Fig. 2 Effects of LLL12 on proliferation in feline OSCC cell lines.
Feline OSCC cell lines were treated with DMSO or LLL12 at increasing
concentrations (0.01-10 μM) for 24 h and proliferation was assessed
using CyQUANT® Cell Proliferation Assay Kit. Experiments were
performed in triplicate and IC50 values were calculated
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expression was observed in the SCCF3 cell line.
As ubiquitin-mediated proteasomal degradation is a
known regulatory mechanism for STAT family protein
turnover [33, 34], SCCF2 cells were treated with the
proteasome inhibitor, MG132, to determine if this
mechanism was responsible for the loss of total STAT3.
Cells were treated with LLL12 alone, MG132 alone or
MG132 in combination with LLL12 for 12 h. Western
blot analysis demonstrated that MG132 did not blockLLL12 mediated downregulation of total STAT3, sug-
gesting that ubiquitin-mediated proteosomal degrad-
ation is not the mechanism responsible for loss of total
STAT3 following LLL12 treatment in feline OSCC cells
(Fig. 3b). Lastly, because STAT3 mRNA expression
levels did not decrease following LLL12 treatment, loss
of total STAT3 was likely not due to autoregulation
whereby pSTAT3 can enhance STAT3 gene transcrip-
tion [35]. Although there was slight decrease in STAT3
mRNA following LLL12 treatment in the SCCF2 cell
line, this difference was not statistically significant
(Fig. 3c).
Treatment with LLL12 promotes apoptosis of feline OSCC
cells that express elevated levels of pSTAT3
To determine if growth inhibition of feline OSCC cells
was mediated by apoptosis, SCCF2 and SCCF3 were
treated with DMSO, 0.02, 0.2, or 2 μM of LLL12 for 12
or 24 h and caspase 3/7 activity was measured. After
12 h of treatment with 0.2 μM of LLL12, SCCF2 showed
a trend towards increased caspase 3/7 activity (data not
shown), but this difference did not reach statistical sig-
nificance until 24 h of treatment. SCCF3 showed a small,
but statistically significant, increase in caspase 3/7 activ-
ity after 24 h of treatment with 2 μM of LLL12 (Fig. 4).
Treatment with LLL12 reduces colony formation in feline
OSCC cells
To further assess the effects of LLL12 on feline OSCC cell
growth, SCCF2 and SCCF3 cells were seeded in 6-well
plates and treated with DMSO or LLL12 and evaluated
daily. Once colony formation was observed in DMSO
treated wells, the plates were collected and colonies were
counted following staining with crystal violet. As shown in
Fig. 5, colony formation was significantly inhibited in both
SCCF2 and SCCF3 at concentrations above 0.02 and
0.2 μM, respectively. Photographs of representative 6-well
plates are shown in Figure 5b.
Effects of LLL12 on STAT3 transcriptional targets
The effect of LLL12 on survivin, a transcriptional target of
STAT3, was assessed by quantitative RT-PCR. Following
12 h of treatment, the expression of survivin was signifi-
cantly downregulated in SCCF2 as demonstrated in Fig. 6a.
A small decrease in survivin protein was also observed fol-
lowing LLL12 treatment as assessed by Western blotting
(Fig. 6b). In contrast, no changes in survivin mRNA or
protein levels were seen in SCCF3.
Quantitative RT-PCR was performed to evaluate the ef-
fects of LLL12 treatment on other STAT3 transcriptional
targets, including cyclin D1, VEGF, and MCL-1. As shown
in Figure 6c, there was no change in cyclin D1 gene expres-
sion in either cell line following treatment with LLL12. In
contrast, there was an approximately 7-fold increase in
Fig. 3 Effects of LLL12 treatment on pSTAT3 and STAT3 expression in feline OSCC cell lines. a Feline OSCC cell lines were treated with DMSO or 0.2 μM
LLL12 for 12 h prior to collection. Protein lysates were generated, separated by SDS-PAGE and Western blotting for pSTAT3, STAT3 and β-actin was
performed. b SCCF2 cells were treatment with 0.2 μM LLL12 alone, 10 μM MG132 alone or MG132 in combination with LLL12 for 12 h. c Feline OSCC cell
lines were treated with DMSO or 0.2 μM LLL12 for 12 h. RNA was collected and quantitative RT-PCR for STAT3 was performed
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Likewise, expression of MCL-1, an anti-apoptotic pro-
tein whose transcription is regulated by both STAT3
and VEGF, was significantly increased in SCCF2 fol-
lowing LLL12 treatment. Finally, as HIF-1α is a known
transcriptional regulator of VEGF activation, mRNA
levels were also assessed by quantitative RT-PCR. As
with VEGF and MCL-1, HIF-1α gene expression was
significantly increased in the SCCF2 cell line following
treatment. In contrast, no significant changes in VEGF,
MCL-1 or HIF-1α gene expression were observed in
the SCCF3 cell line.
Activation of the PI3K/AKT/mTOR is not responsible for
up-regulation of VEGF, MCL-1 and HIF-1α gene expression
following LLL12 treatment
To determine if activation of the PI3K/AKT/mTOR
pathway is responsible for the observed up-regulation of
VEGF, MCL-1 and HIF-1α gene expression in SCCF2
following LLL12 treatment, we evaluated the expression
and phosphorylation status of AKT in these cells after
12 h of drug exposure. Western blotting demonstrated
low levels of basal AKT phosphorylation in SCCF2,
which remained unchanged after treatment with LLL12
(Fig. 7).Immunohistochemical expression of pSTAT3 in primary
feline OSCC tumor samples
To assess the prevalence of STAT3 activation in primary fe-
line OSCC samples, a tissue microarray was constructed
from 37 archived feline OSCC surgical biopsies and immu-
nohistochemical staining for pSTAT3 was performed. Signal
intensity and percent positivity were scored; these scores
were added to generate a total score. Examples of no, mild
and moderate signal intensity are shown in Figures 8a-c.
Total scores of greater than or equal to 2 were considered
positive. Of 37 samples, 27 had adequate tumor tissue for
evaluation and 13 of these 27 (48.1 %) samples were consid-
ered positive. In 9 of the 13 positive samples, immunoreac-
tivity was detected in 5–20 % of OSCC cells, while 3 and 1
sample displayed immunoreactivity in 20–50 % and
50–100 % of cells, respectively. In 4 samples, pSTAT3
expression was also observed in adjacent gingiva
(Fig. 8d), although 2 of these 4 samples were considered
to have inadequate tumor sample and were excluded
from analysis. The results of the TMA scoring are sum-
marized in Additional file 1: Table S2.
Discussion
Feline oral squamous cell carcinoma is a devastating cancer,
for which effective treatments are lacking. It shares several
Fig. 4 Evaluation of feline OSCC cell lines for apoptosis following LLL12
treatment. Feline OSCC cell lines were treated with DMSO or increasing
concentrations of LLL12 (0.2 – 2 μM) for 24 h. Caspase activity was
assessed using SensoLyte Homogenous AMC Caspase 3/7 Assay kit.
Experiments were performed in triplicate (*p < 0.05)
Fig. 5 Impact of LLL12 on colony formation in feline OSCC cell lines.
a Feline OSCC cells were seeded at 1,000 cells per well in 6 –well
plates for 24 h, followed by treatment with DMSO, 0.02, 0.2 or 2 μM
LLL12 until formation of visible colonies. Cells were then fixed and
stained with crystal violet and colonies greater than 50 cells were
counted. After counting colonies, plating efficiency and survival
fraction were calculated. Plating efficiency was defined as the
number of colonies formed divided by the number of cells seeded
in DMSO treated groups. Survival fraction was defined as the number
of colonies formed divided by the number of cells seeded in LLL12
treated groups, normalized to the plating efficiency (*p < 0.0001).
b Photographs of representative 6-well plates
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tumor biology (both tumors are locally invasive and cause
malignant osteolysis), molecular markers (EGFR, p53) and
poor response of advanced stage disease to conventional
therapies [36, 37]. In humans, key risk factors for develop-
ment of HNSCC have been identified and include tobacco
use, alcohol consumption and human papillomavirus (HPV)
infection. In contrast, the etiopathogenesis of feline OSCC is
not well understood. Although papillomavirus DNA has
been isolated from feline cutaneous and nasal planum SCC
[38, 39], no viral DNA was amplified in a series of 30 feline
OSCC samples [40]. Retrospective, case-controlled studies
have identified potential risk factors for development of
feline OSCC, including use of flea control products, diet
and exposure to environmental tobacco smoke [41, 42].However, given the retrospective nature of these
studies, a cause and effect relationship cannot be de-
finitively determined.
Fig. 6 Effects of LLL12 on transcriptional targets of STAT3. Feline OSCC cells were treated with DMSO or 0.2 μM LLL12 for 12 h and RNA and
protein were collected. Quantitative RT-PCR (a) and Western blotting (b) were performed to assess survivin mRNA and protein levels, respectively
(*p < 0.0001). (c) Quantitative RT-PCR was performed to assess cyclin D1, MCL-1, VEGF and HIF1α mRNA expression in the cells treated above (*p < 0.05)
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treatments for feline OSCC, few studies have investi-
gated the molecular abnormalities that promote the de-
velopment of this cancer and drive resistance to therapy.
As with humans, activation of the epidermal growth fac-
tor receptor (EGFR) may be important as this has been
shown to be widely expressed in feline OSCC tumor
samples [43, 44] and EGFR inhibition by a smallmolecule inhibitor and RNA interference resulted in re-
duced proliferation and migration in a feline cell line
[45]. However, dysregulation of other signaling pathways
is poorly characterized.
In HNSCC, several potential contributors to disease
pathogenesis have been identified including activation
of STAT3 signaling. Specifically, phosphorylated STAT3
has been shown to be upregulated in both tumor and
Fig. 7 Evaluation of PI3K/AKT/mTOR signaling pathway in feline OSCC.
Feline OSCC cells were treated with DMSO or 0.2 μM LLL12 for 12 h.
Cells were harvested and total protein isolated followed by SDS-PAGE
and Western blotting for pAKT, AKT and β-actin
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to epithelium from non-cancer patients [12]. Further-
more, multiple studies have demonstrated that in-
creased levels of activated STAT3 in patient tumor
samples is associated with tumor stage, nodal metasta-
sis and decreased survival [14, 46, 47], although con-
flicting reports also exist [48, 49]. Recently, a phase 0
clinical trial evaluating a STAT3 decoy oligonucleotide
demonstrated decreased expression of STAT3 target
genes in head and neck tumors following intratumoral
injection [9]. Given the emerging role of STAT3 in hu-
man HNSCC, we elected to evaluate its potential func-
tion in the feline disease. Our collaborator (C. Lin,
College of Pharmacy, OSU) has developed a small mol-
ecule, allosteric STAT3 inhibitor (LLL12) that exhibits
broad activity against both human and canine cancer
cell lines at concentrations in the nanomolar/low mi-
cromolar range [24, 50]. The purpose of this study was
to characterize the expression of pSTAT3 in feline
OSCC cell lines and tumor samples and to investigate
the effects of LLL12 in feline OSCC cell lines.
Our initial work showed that one cell line, SCCF2, had
high levels of pSTAT3 compared to the other two OSCC
cell lines. Although treatment with LLL12 significantly
reduced proliferation in all cell lines, SCCF2 was the
most sensitive to drug exposure (IC50 = 180 nM), cor-
relating with the highest level of basal pSTAT3. Wefurther evaluated the effects of LLL12 on cell prolifera-
tion with colony formation assays in high and low
pSTAT3 expressing cell lines, (SCCF2 and SCCF3, re-
spectively). Colony formation was significantly reduced
in both cell lines; however, this occurred at a drug con-
centration 10 times lower for SCCF2 (20 nM) com-
pared to the SCCF3 line (200 nM), providing further
support for STAT3 specific effects. In both cell lines,
inhibition of colony formation occurred at concentra-
tions well below the calculated IC50 values. While the
exact reason for this discordance is not known, consti-
tutive STAT3 phosphorylation has been previously as-
sociated with enhanced colony formation [51]. In
contrast to our study, effects on colony formation with
other STAT3 inhibitors generally occurred at drug con-
centrations approximating IC50 values [52, 53] suggest-
ing that other factors (i.e. culture conditions, anchorage
dependence, etc.) may have influenced the sensitivity of
our feline OSCC lines to LLL12.
Treatment of SCCF2 with LLL12 resulted in downregu-
lation of both pSTAT3 and STAT3 protein expression.
Mechanisms of STAT3 protein downregulation include
autoregulation of gene transcription and ubiquitin-
mediated proteasomal degradation [33–35]. However,
STAT3 mRNA levels were unchanged following LLL12
treatment and concurrent treatment with a proteasome
inhibitor failed to reverse STAT3 downregulation, sug-
gesting that neither of these mechanisms are respon-
sible for the observed decreased in STAT3 protein.
Other potential reasons for loss of total STAT3 include
caspase-dependent proteolysis [54] and post-transcriptional
modification by microRNAs [55].
Apoptosis of SCCF2 cells, as detected via caspase 3/7
activity, occurred at concentrations of LLL12 that re-
duced pSTAT3 expression, indicating that pSTAT3 in-
hibition may lead to apoptosis. One possible mechanism
of apoptosis is downregulation of STAT3 transcriptional
targets, which include anti-apoptotic genes. In support
of this, survivin mRNA was significantly downregulated
following treatment with LLL12; however, only a rela-
tively small concomitant decrease in survivin protein
was observed. This may be due to the prolonged pres-
ence of existing survivin protein, necessitating significant
turnover before downregulation would be noted by west-
ern blotting, as previously described [50]. Importantly,
SCCF3, a cell line with minimal basal pSTAT3, showed
no change in survivin mRNA or protein levels, once
again supporting a STAT3 specific effect.
To assess the prevalence of basal STAT3 phosphorylation
in primary feline OSCC tissue samples, we constructed a
TMA from archival formalin-fixed paraffin embedded tis-
sue samples and performed IHC for pSTAT3. Based on our
scoring criteria, 13 of 27 (48.1 %) samples that had ad-
equate tissue for analysis were considered positive. This
Fig. 8 Immunohistochemistry for pSTAT3 in primary feline OSCC tumor samples. Immunohistochemistry was performed for pSTAT3 using a tissue
microarray of feline OSCC tumor samples. Signal intensity and percent positivity were scored; these scores were added to generate a total score.
Examples of no (a), mild (b) and moderate (c) signal intensity are shown (20X). d pSTAT3 immunoreactivity was also observed in adjacent
gingiva in 4 OSCC samples (10X)
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chemical studies that have demonstrated nuclear pSTAT3
immunoreactivity in 37–67 % of HNSCC tissue samples
[14, 56]. It is difficult to compare studies due to differ-
ing methodologies employed, including those used to
define STAT3 activation. In the current investigation
we used nuclear accumulation of pSTAT3 as an indica-
tor of activation. Other studies have relied on nuclear
localization of unphosphorylated STAT3 or increased
nuclear or cytoplasmic levels of unphosphorylated
STAT3 as compared to control tissues [48, 57]. Inter-
pretation of STAT3 activation is complicated by the
discovery that unphosphorylated STAT3 can also enter
the nucleus and activate gene expression via acetylation
of other sites on the protein [58, 59]. Nevertheless, the
presence of pSTAT3 in nearly half of the tumors ex-
amined indicates that this transcription factor is acti-
vated in a substantial proportion of feline OSCC.
Given the lack of complete patient information and
follow-up accompanying the archival feline tumor sam-
ples, it was not possible to determine the prognostic sig-
nificance of nuclear pSTAT3 immunoreactivity in feline
OSCC. In 9 of the 13 samples that were considered posi-
tive, immunoreactivity was detected in less than 20 % of
tumor cells. Reasons for this low percentage of positivity
include tumor heterogeneity, sample aging and effects of
and variation in fixation methods. Another possibility isthat STAT3 activation is an early step in feline OSCC car-
cinogenesis and reliance on STAT3 signaling pathways is
lost in later stages of tumor development. This theory is
supported by HNSCC studies that have demonstrated in-
creased STAT3 activation in normal mucosa from patients
with HNSCC as well as in pre-malignant lesions such as
leukoplakia [12, 14]. In addition, decreasing STAT3 activa-
tion with increasing tumor grade has also been observed
[57]. As most cases of feline OSCC are diagnosed at an
advanced stage, our results may support loss of STAT3 ac-
tivation with tumor progression although further work is
needed to investigate the expression of STAT3 in early
tumorigenesis. Interestingly, pSTAT3 immunoreactivity
was observed in adjacent mucosa in a handful of feline
OSCC samples, which may further support the theory of
early STAT3 activation.
One of the more intriguing findings in this study was the
upregulation of expression of several STAT3 transcrip-
tional targets, VEGF, MCL-1 and HIF-1α following LLL12
treatment. It is possible that the HIF-1α upregulation is re-
sponsible for the observed increase in VEGF and MCL-1,
although the mechanism for HIF-1α up-regulation is not
yet known. Moreover, several other studies have demon-
strated downregulation of these targets following STAT3
inhibition [12, 25, 46, 50, 60], suggesting that feline OSCC
may utilize different pathways to regulate the expression of
these genes.
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itional signaling pathways in feline OSCC, we assessed levels
of pAKT/total AKT in the SCCF2 line. The PI3K/AKT/
mTOR pathway regulates a diverse set of oncogenic
processes including cellular survival, metastasis, angio-
genesis and glucose metabolism. This pathway is of par-
ticular interest in HNSCC as it is frequently mutated in
primary HNSCC tumors [61] and may represent a
mechanism of resistance to anti-EGFR therapy [62].
Furthermore, studies on the involution of mammary
gland epithelial cells have demonstrated a role for
STAT3 in downregulation of PI3K-AKT signaling via
STAT3 mediated expression of PI3K regulatory sub-
units [63]. We observed no upregulation of pAKT fol-
lowing LLL12 treatment, suggesting that STAT3 does
not negatively regulate this pathway in feline OSCC
and that enhanced AKT activation is not responsible
for the observed increase in HIF-1α.
Signaling pathway cross-talk and redundancy may also
help explain our unexpected results regarding VEGF, MCL-
1 and HIF-1α expression. For example, studies have dem-
onstrated that STAT3 regulates HIF-1α expression through
multiple mechanisms including direct activation of gene
transcription and promotion of protein stabilization
[64–66]. In contrast, another study showed that HIF-1α, in
cooperation with heat shock protein 90, regulates STAT3
activation and expression in colorectal cancer cells [67].
These findings underscore the complexity of STAT3 signal-
ing pathways. Finally, cellular context may also influence
the nature of STAT3 signaling. In contrast to its generally
accepted role as an oncogene, a growing number of recent
studies have demonstrated a growth suppressive function
of pSTAT3 due to its activation of genes that inhibit
tumorigenesis, including p21 and members of the FOX
family of transcription factors [68]. This is further sup-
ported by work in tumor cell lines showing that STAT3 is a
negative regulator of tumor growth in certain cancers such
as thyroid carcinoma [69]. Although the results of our
study are most supportive of growth stimulating role of
STAT3 in feline OSCC, the upregulation of STAT3 target
genes following LLL12 treatment indicate that STAT3 in-
hibition may be most effective when used in combination
with other therapeutics.
Conclusions
These data demonstrate that LLL12 has biologic activity
against a feline OSCC cell line with constitutive STAT3
phosphorylation. In addition, pSTAT3 expression was
detected in 48 % of feline OSCC tumor samples, further
supporting STAT3 as a potential therapeutic target in
this disease. However, LLL12 treatment also resulted in
upregulation of several STAT3 transcriptional targets,
suggesting that further research into the role of STAT3
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